289 related articles for article (PubMed ID: 34481810)
1. Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A Five-Year Experience.
Chen S; Ren H; He Y; An J; Zhang Y
J Oral Maxillofac Surg; 2021 Dec; 79(12):2472-2481. PubMed ID: 34481810
[TBL] [Abstract][Full Text] [Related]
2. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
[TBL] [Abstract][Full Text] [Related]
4. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
8. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Wazzan T; Kashtwari D; Almaden WF; Gong Y; Chen Y; Moreb J; Katz J
Spec Care Dentist; 2018 Nov; 38(6):356-361. PubMed ID: 30194738
[TBL] [Abstract][Full Text] [Related]
9. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
10. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
[TBL] [Abstract][Full Text] [Related]
12. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
13. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
14. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement.
Sánchez-Gallego Albertos C; Del Castillo Pardo de Vera JL; Viejo Llorente A; Cebrián Carretero JL
Med Oral Patol Oral Cir Bucal; 2021 Nov; 26(6):e684-690. PubMed ID: 34704981
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing Severity of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.
Feng Z; An J; Zhang Y
J Oral Maxillofac Surg; 2021 Aug; 79(8):1683-1688. PubMed ID: 33529608
[TBL] [Abstract][Full Text] [Related]
16. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management.
Tani M; Hatano K; Yoshimura A; Horibe Y; Liu Y; Sassi N; Oka T; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Nonomura N
Sci Rep; 2024 Jun; 14(1):13451. PubMed ID: 38862617
[TBL] [Abstract][Full Text] [Related]
17. Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.
Hadad H; Matheus HR; Pai SI; Souza FA; Guastaldi FPS
Arch Oral Biol; 2024 Mar; 159():105875. PubMed ID: 38160519
[TBL] [Abstract][Full Text] [Related]
18. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal TW; Schlieve T
J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
Adachi N; Ayukawa Y; Yasunami N; Furuhashi A; Imai M; Sanda K; Atsuta I; Koyano K
Sci Rep; 2020 Mar; 10(1):5620. PubMed ID: 32221325
[TBL] [Abstract][Full Text] [Related]
20. Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing.
Zheng Y; Dong X; Chen S; He Y; An J; Liu M; He L; Zhang Y
BMC Oral Health; 2023 Jan; 23(1):14. PubMed ID: 36627695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
